-
2026-06-24
GenSci's Triptorelin Acetate for Injection (II) Secures NMPA Approval for Central Precocious PubertyLearn More
-
2026-06-04
GenSci: Two Innovations Granted IND Clearance by FDALearn More
-
2026-05-28
Dr. Lei Jin of GenSci Shines at J.P. Morgan Global China Summit, Sharing Insights on Innovation and GlobalizationLearn More
-
2026-05-19
GenSci's Innovative IL-1α/β Bispecific Antibody Receives First FDA Clinical ApprovalLearn More
-
2026-05-15
GenSciP166 Selected as Late-Breaking Abstract at SID 2026Learn More
-
2026-05-07
GenSci's Firsekibart Injection Receives Approval by NMPALearn More
-
2026-04-29
GenSci’s NK3R Antagonist for VMS Phase II Study Results Published in MenopauseLearn More
-
2026-04-27
GenSci Presents Multiple Innovative Oncology Pipelines at AACR 2026Learn More
-
2026-03-17
Positive Phase II Results for GenSci's Firsekibart in Pediatric Rare Disease PublishedLearn More
-
2026-03-11
GenSci128, an Investigational Cancer Therapy from Gensci Pharmaceuticals, Receives FDA Orphan Drug Designation for Pancreatic CancerLearn More
-
2026-02-14
GenSci136, an APRIL/BAFF Dual Antagonist, Granted Clinical Trial Approval for IgANLearn More